Int J Gynecol Cancer 2016 11;26(9):1642-1649
*Pritzker School of Medicine, The University of Chicago, Chicago, IL; †Drexel University College of Medicine, Philadelphia, PA; ‡Department of Gynecology-Oncology, and §Department of Radiation and Cellular Oncology, The University of Chicago, Chicago IL.
Objective: Preclinical data and recent epidemiological studies suggest that statins have antiproliferative and antimetastatic effects in various cancer cells, and reduce cancer mortality and recurrence. We study the effect of statin use on survival outcomes and recurrence rates in patients with endometrial cancer with high-risk histology.
Materials And Methods: All patients receiving definitive therapy for high-risk endometrial cancer from 1995 to 2014 were retrospectively reviewed. Health characteristics at baseline were collected, and statin use was determined from medical records. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using the log-rank test. Cox proportional hazards regression models were used for univariate and multivariate analysis to determine independent factors associated with OS and PFS.
Results: A total of 199 patients were included in the study, of which 76 were hyperlipidemic and 50 used statins. The median follow-up time was 31 months from time of diagnosis. Hyperlipidemic patients who used statins had improved OS compared with hyperlipidemic patients not using statins (hazard ratio, 0.42; 95% confidence interval, 0.20-0.87; P = 0.02). Statin use was also associated with improved PFS (hazard ratio, 0.47; 95% confidence interval, 0.23-0.95; P = 0.04) on multivariate analysis. Hyperlipidemic patients who used statins had borderline improved freedom from local failure compared with hyperlipidemic cases not using statins (P = 0.08, log-rank test). Statin use was not found to be associated with improved cancer-specific mortality.
Conclusions: Statin use is independently associated with significant improvements in PFS for the overall group and PFS and OS in the hyperlipidemic group.